VisCardia Secures $40 Million Growth Financing to Advance VisONE™ Heart Failure Therapy Toward PMA Approval
Pioneered Synchronized Diaphragmatic Stimulation Therapy
The financing will support the execution of the company’s pivotal RECOVER-HF clinical study, and key milestones on the path to PMA. VisCardia expects to achieve the first implant early in 2026. Multiple leading U.S. institutions have already passed site qualification and are nearing patient enrollment, with a strong pipeline of both national and international institutions to follow.
“Closing this $40 million financing marks a transformative milestone for VisCardia,” said Peter Bauer, Ph.D., President & CEO of VisCardia. “We are now positioned to execute our U.S. IDE pivotal trial and accelerate development of a minimally invasive therapy designed to offer a new treatment pathway for millions of heart failure patients who remain symptomatic despite guideline-directed medical therapy. The strong support from our investors underscores the magnitude of this unmet need and the differentiated potential of VisONE Therapy.”
Dr. Lee Goldberg, Section Chief for Advanced Heart Failure and Cardiac Transplant at the University of Pennsylvania, will serve as Principal Investigator for RECOVER-HF. “I am very excited to be leading this pivotal trial,” said Dr. Goldberg. “VisONE represents a promising and intuitive therapy for the substantial population of heart failure patients who continue to struggle despite adherence to established medical therapy. The mechanism of action leverages the diaphragm’s natural physiologic contribution to cardiac function in a low-risk, minimally invasive manner. This unique approach aligns with the long-term treatment and economic goals in this complex patient population.”
VisONE is a truly novel Heart Failure device therapy designed to augment cardiac function by stimulating the diaphragm in synchrony with the cardiac cycle, thereby using it as an ancillary cardiac pump to improve blood circulation. The therapy does not interfere with respiration and is imperceptible to the patient. The extra-cardiac/thoracic placement VisONE enables a minimally invasive laparoscopic implant procedure that can be performed by a wide range of surgeons in an outpatient setting.
The RECOVER-HF pivotal trial will be a randomized, double-blinded study enrolling approximately 270 patients with moderate to severe heart failure who remain symptomatic despite optimized medical therapy and preserved ventricular synchrony. VisCardia has completed multiple OUS feasibility studies demonstrating clinically meaningful improvements in symptoms, functional capacity, and hemodynamic parameters.
About VisCardia
VisCardia, Inc. is a privately held medical device company based in Portland, Oregon, dedicated to developing minimally invasive solutions for the millions of patients suffering from heart failure. The company’s breakthrough VisONE™ Synchronized Diaphragmatic Stimulation Therapy has completed extensive preclinical and early human clinical evaluation, and has been granted Breakthrough Device designation by the U.S. FDA. VisCardia is preparing to launch its pivotal RECOVER-HF trial, enrolling up to 30 sites across the U.S. and Europe, as it advances toward PMA approval.
For more information, visit: www.viscardia.com
Jennifer Matson
VisCardia
matsonj@viscardia.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
